6-KThe Wire
Lakefront Biotherapeutics NV files 6-K
Filed Mar 31, 2026 · 3mo ago · Accession 0001193125-26-132908
Plain English
Galapagos NV announced a binding agreement with Gilead to collaborate on a first-in-class T cell engager program for autoimmune diseases. This collaboration is detailed in a press release and corporate presentation dated March 31, 2026.
Filing details
- Company
- Lakefront Biotherapeutics NV
- Ticker
- LKFT
- CIK
- 1421876
- Form type
- 6-K
- Filing date
- Mar 31, 2026
- Report date
- Mar 31, 2026
- Document
- d927249d6k.htm
- Size
- 8.0 MB